IMS HEALTH Launches New Online Store Offering Instant Access to Global Pharmaceutical Information 2/6/00 IMS HEALTH has set up open.imshealth.com, a new Internet-based information resource that provides immediate, one-stop access to a wealth of global pharmaceutical industry information. More than 10,000 reports, covering the latest sales, analyses and forecasts by therapy class and region, along with profiles of key pharmaceutical companies, are available for credit card purchase and instant download. According to Justin Sprunt, marketing manager at IMS HEALTH, "open.imshealth.com is the industry's online resource for global pharmaceutical industry information. Anyone with Internet access can now browse, search and purchase unique IMS HEALTH pharmaceutical information on an 'as needed' basis, 24 hours a day. Pharmaceutical executives, consultants, financial analysts, journalists and others anywhere in the world can choose from reports about new drug launches, the growth of products and therapeutic classes, and the latest industry trends. " Information available via open.imshealth.com covers the entire drug lifecycle, from discovery to off-patent, along with additional company and sales information. Reports and Profiles include: Sales Reports that review the top 20 international drugs in all major therapy areas across the world's strategic markets. The reports, available as Microsoft ExcelTM tables, include two years of sales, market share and growth data during the previous 12 months. Analysis and Forecasts, covering eight countries and 40 therapy areas, feature ten-year forecasts, overviews that include disease classifications and treatments, and listings of significant market events. Analytic reports document the latest in R&D in over 130 areas, showing the drugs that have the potential to dominate the market in their classes. Pharmaceutical Company Profiles for investment or competitive analysis that provide detailed analyses and summaries of 100 major companies' business strategies and operations. The Profiles include reviews of financial performance, R&D pipelines, product portfolios and major events affecting each company, such as licensing and mergers and acquisitions activity. Reports are also available which segment company sales performance by therapy area, and others detailing complete product pipelines for over 1,000 companies and research institutes. Sales figures for 180 pharmaceutical companies, and consolidated sales from 13 of the world's key markets are also available.